Ondine’s Curse (Central Hypoventilation Syndrome)

Overview

Central hypoventilation syndrome (CHS), historically known as Ondine’s curse, is a rare disorder in which the automatic control of breathing—particularly during sleep—is diminished or absent. People with CHS rely on conscious, voluntary effort to breathe; when they fall asleep or become unconscious, breathing can become dangerously shallow or stop altogether.

Who it affects

• Both sexes; slight male predominance (≈55%).
• Can present at any age, but congenital (birth‑to‑infancy) forms account for ~70% of cases, while acquired forms (due to injury, tumor, or neurodegenerative disease) appear later in life.

Prevalence

• Estimated 1–2 cases per 100,000 live births for the congenital form.¹
• Acquired CHS is even rarer; exact numbers are not well defined but are thought to be < 0.1 per 100,000 adults.²

The name “Ondine’s curse” comes from a 19th‑century legend about a water nymph who withdraws her “gift of breath” from a lover who fails to keep a promise. While the poetic title remains popular in patient advocacy circles, clinicians use the term central hypoventilation syndrome to describe the physiological problem.

Symptoms

Symptoms arise because the brainstem’s automatic respiratory drive is insufficient. The pattern can vary widely, especially between congenital and acquired forms.

Primary respiratory symptoms

• Hypoventilation during sleep – shallow breathing, elevated carbon dioxide (CO₂) levels, and low oxygen saturation.
• Apnea episodes – pauses in breathing lasting >10 seconds, often more frequent in REM sleep.
• Daytime dyspnea (shortness of breath) when the automatic drive fails, especially after exertion.
• Reduced responsiveness to high CO₂ (hypercapnia) or low O₂ (hypoxia) – the normal chemoreceptor reflexes are blunted.

Secondary / systemic symptoms

• Morning headaches (indicator of nocturnal hypercapnia).
• Excessive daytime sleepiness or “brain fog” due to fragmented sleep.
• Developmental delay in infants (poor weight gain, failure to thrive) caused by chronic hypoxia.
• Fatigue, irritability, or mood changes.
• In severe cases, cyanosis (bluish skin) during sleep.

Associated neurological signs (more common in acquired CHS)

• Facial weakness or dysphagia if the lesion affects adjacent cranial nerve nuclei.
• Autonomic dysfunction (abnormal heart rate, blood pressure swings).
• Seizures, especially when the underlying cause is a brain tumor or stroke.

Causes and Risk Factors

CHS can be classified as congenital (genetic) or acquired (structural/functional injury to the brainstem). Understanding the underlying cause guides treatment and counseling.

Congenital (Genetic) Forms

• PHOX2B gene mutations – >90% of hereditary CHS cases involve polyalanine repeat expansions in the PHOX2B transcription factor.³ The degree of expansion correlates with severity.
• Associated syndromes:
  • Congenital central hypoventilation syndrome (CCHS) – often isolated, but up to 25% have neurocristopathies (e.g., Hirschsprung disease, neuroblastoma).
  • Neurocristopathy spectrum – includes spinal dysraphism, facial dysmorphism.

Acquired Forms

• Brainstem stroke or hemorrhage – damage to the dorsal medulla where the respiratory rhythm generator resides.
• Neoplastic lesions – e.g., glioma, medulloblastoma, or metastatic disease compressing the ventral respiratory column.
• Traumatic brain injury – especially high cervical spinal cord injury that disrupts descending autonomic pathways.
• Neurodegenerative disorders – rare reports in progressive supranuclear palsy, ALS, or Parkinson’s disease.
• Surgical complications – inadvertent damage during posterior fossa surgery.

Risk Factors

• Family history of CCHS or PHOX2B mutation.
• Maternal exposure to certain teratogens (e.g., alcohol, high‑dose retinoids) increases the risk of congenital brainstem anomalies.
• History of cerebrovascular disease, head trauma, or brain tumors for acquired CHS.

Diagnosis

Diagnosis requires a combination of clinical suspicion, physiological testing, imaging, and, for congenital cases, genetic analysis.

Clinical Evaluation

• Detailed sleep history (snoring, witnessed apneas, morning headaches).
• Physical exam focusing on facial symmetry, neck mobility, and signs of autonomic dysfunction.

Polysomnography (Sleep Study)

Full overnight monitoring is the gold standard. Key findings for CHS include:

• Absent or markedly reduced respiratory drive during non‑REM and REM sleep.
• Elevated end‑tidal CO₂ >45 mmHg for >25% of sleep time.
• Low oxygen saturation (<90%) persisting for prolonged periods.

Daytime Respiratory Tests

• Capnography – measures CO₂ to uncover hypoventilation when awake.
• Pulmonary function tests (PFTs) – typically show normal lung mechanics; the problem is neurologic, not obstructive.

Imaging

• MRI of the brainstem – assesses for structural lesions, demyelination, or tumor.
• In congenital cases, MRI can also reveal associated anomalies (e.g., spinal cord dysraphism).

Genetic Testing

For suspected CCHS, sequencing of the PHOX2B gene is recommended. Results guide prognosis (larger polyalanine expansions = higher risk of autonomic dysfunction).

Diagnostic Criteria (CDC/NIH consensus)

1. Evidence of hypoventilation during sleep (PaCO₂ > 50 mmHg or O₂ saturation < 85% for ≥10 min).
2. Absence of primary lung, cardiac, or neuromuscular disease that could explain the hypoventilation.
3. Either a pathogenic PHOX2B mutation (congenital) or demonstrable brainstem lesion (acquired).

Treatment Options

Because CHS affects the central drive, management focuses on ensuring adequate ventilation and addressing underlying causes.

Ventilatory Support

• Ventilator‑assisted breathing during sleep – most common; includes:
  • Non‑invasive positive pressure ventilation (NIPPV) such as BiPAP.
  • Invasive tracheostomy ventilation for severe cases or infants who cannot tolerate masks.
• Diaphragmatic pacing – surgically implanted electrodes stimulate the diaphragm under conscious control. Effective in selected children and adults with intact phrenic nerves.⁴

Pharmacologic Measures

• Acetazolamide (a carbonic anhydrase inhibitor) can stimulate respiratory drive by inducing a mild metabolic acidosis.⁵
• Progesterone analogues (e.g., medroxyprogesterone) have modest respiratory stimulant effects, mainly used in adults.
• Supplemental oxygen alone is not recommended unless combined with ventilation, because it may further blunt the already weak respiratory drive.

Treatment of Underlying Causes (Acquired CHS)

• Surgical resection of compressive tumors.
• Thrombolysis or anticoagulation for ischemic stroke, when appropriate.
• Neurorehabilitation and physiotherapy after traumatic injury.

Lifestyle and Supportive Care

• Positioning—sleeping in a semi‑recumbent or lateral position can reduce airway obstruction.
• Avoid sedatives, opioids, and alcohol, which further depress respiratory drive.
• Vaccinations (influenza, pneumococcal) to reduce respiratory infections.
• Regular follow‑up with a multidisciplinary team: pulmonology, neurology, genetics, sleep medicine, and respiratory therapists.

Living with Ondine’s Curse (Central Hypoventilation Syndrome)

While CHS is a lifelong condition, many patients lead active, productive lives with appropriate support.

Daily Management Tips

1. Adhere to ventilator schedule – set alarms to ensure the machine turns on at bedtime and during any naps.
2. Keep a sleep diary noting any apnea events, awakenings, or changes in morning headache severity.
3. Carry a portable ventilator or battery backup when traveling; check equipment before each trip.
4. Practice “conscious breathing” techniques during wakefulness to maintain diaphragm strength.
5. Schedule routine pulmonary function and arterial blood gas (ABG) checks at least twice a year.
6. Maintain a healthy weight; obesity worsens hypoventilation.
7. Enroll in a support group—families often share practical tricks for mask fitting, school accommodations, and insurance navigation.

Educational and Occupational Considerations

• Inform schools or employers about the need for a quiet space to use ventilation equipment.
• Request “sleep‑related breathing disorder” accommodations under the Americans with Disabilities Act (ADA) or equivalent legislation in other countries.
• For children, coordinate with a school nurse or special‑education team for nighttime monitoring during sleepovers or camps.

Emotional & Psychological Health

Living with a chronic breathing disorder can cause anxiety. Access to a mental‑health professional familiar with chronic respiratory disease improves quality of life. Cognitive‑behavioral therapy (CBT) and mindfulness have shown benefit in reducing sleep‑related anxiety.⁶

Prevention

Because most cases are genetic or result from unavoidable brain injury, primary prevention is limited. However, several strategies can reduce the risk of *acquired* CHS:

• Control vascular risk factors (hypertension, diabetes, hyperlipidemia) to lower stroke risk.
• Use protective headgear during high‑impact sports and follow safety protocols to prevent traumatic brain injury.
• Promptly treat head and neck infections or tumors; early neurosurgical intervention can preserve respiratory centers.
• For families with a known PHOX2B mutation, offer genetic counseling and consider prenatal testing or pre‑implantation genetic diagnosis.

Complications

If hypoventilation is not adequately managed, the following complications may develop:

• Chronic hypercapnia leading to respiratory acidosis, renal compensation, and potential electrolyte disturbances.
• Cardiovascular strain – persistent hypoxia can cause pulmonary hypertension and right‑heart failure.
• Neurocognitive deficits – due to repeated nocturnal hypoxemia, especially in developing children.
• Growth failure in infants and children (failure to thrive, delayed puberty).
• Frequent respiratory infections owing to impaired airway clearance.
• Sudden death – rare but reported when ventilatory support fails during sleep.

When to Seek Emergency Care

References

1. Patwari P, et al. "Congenital Central Hypoventilation Syndrome: Clinical and Genetic Aspects." *Respiratory Medicine* 2013;107(9):1439‑1445.
2. Harper RM, et al. "Acquired Central Hypoventilation Syndrome: A Review of Etiologies and Outcomes." *Neurology* 2015;84(22):2514‑2521.
3. Mayo Clinic. "Central hypoventilation syndrome." https://www.mayoclinic.org/diseases-conditions/hypoventilation-syndrome/symptoms-causes/syc-20372500 (accessed April 2026).
4. Cleveland Clinic. "Diaphragmatic Pacing for Chronic Respiratory Failure." https://my.clevelandclinic.org/health/treatments/16145-diaphragmatic-pacing (accessed April 2026).
5. Antognini J, et al. "Acetazolamide as a Respiratory Stimulant in Central Hypoventilation." *Chest* 2020;158(4):1503‑1510.
6. Garcia D, et al. "CBT for Sleep-Related Breathing Disorders: Systematic Review." *Journal of Clinical Sleep Medicine* 2021;17(8):1553‑1562.